Paper Details

  1. Home
  2. Paper Details

Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials.

Author: BuzzoniRoberto, CarnaghiCarlo, FazioNicola, HerbstFabian, KulkeMatthew H, PavelMarianne E, RidolfiAntonia, StrosbergJonathan, ValleJuan W, YaoJames C

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Hyperglycemia and hypercholesterolemia did not have a significant impact on PFS in patients treated with everolimus.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Hyperglycemia and hypercholesterolemia are class effects of mammalian target of rapamycin inhibitors such as everolimus. This post hoc pooled analysis assessed the potential impact of these events on the efficacy of everolimus. METHODS: Patients with advanced, low- or intermediate-grade...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/cncr.33540

データ提供：米国国立医学図書館（NLM）

Everolimus and Neuroendocrine Tumors: A Journey Through the Desert of Side Effects

This pooled analysis explores the relationship between metabolic toxicity and efficacy of everolimus, a mammalian target of rapamycin (mTOR) inhibitor, in patients with neuroendocrine tumors. The authors investigated the potential impact of hyperglycemia and hypercholesterolemia, common side effects of everolimus, on the drug’s efficacy, drawing data from two large clinical trials (RADIANT-3 and RADIANT-4).

What Does this Study Suggest?

The study suggests that although hyperglycemia and hypercholesterolemia are common side effects of everolimus, they do not appear to significantly impact the drug’s efficacy in terms of progression-free survival. It’s like navigating a desert with a few prickly bushes along the way; the journey may be slightly less comfortable, but the destination remains the same.

Implications for Health and Lifestyle

This study provides valuable insights for healthcare providers managing patients with neuroendocrine tumors, offering guidance on the potential benefits and risks of everolimus therapy. Careful monitoring of metabolic parameters is important, but these side effects should not necessarily preclude the use of everolimus in appropriate patients.

Dr.Camel's Conclusion

This research sheds light on the complex interplay between drug efficacy and potential side effects. It reminds us that even in the desert of cancer treatment, we need to weigh the potential benefits and risks carefully to find the best path forward for our patients.

Date :
  1. Date Completed 2022-03-08
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

33857327

DOI: Digital Object Identifier

10.1002/cncr.33540

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.